Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 Combined with Sorafenib in Advanced HCC Patients with Stable Disease
NCT05113290Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Oncorine in hepatocellular carcinoma (HCC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05113290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113290.